BrainsWay Ltd. (NASDAQ:BWAY) Shares Sold by Legato Capital Management LLC

Legato Capital Management LLC decreased its position in shares of BrainsWay Ltd. (NASDAQ:BWAY) by 22.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 90,746 shares of the company’s stock after selling 26,466 shares during the period. Legato Capital Management LLC’s holdings in BrainsWay were worth $856,000 as of its most recent SEC filing.

Separately, JPMorgan Chase & Co. increased its position in BrainsWay by 316.3% during the third quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock worth $136,000 after buying an additional 11,221 shares during the period. Hedge funds and other institutional investors own 30.11% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of BrainsWay in a research report on Monday, December 23rd.

BrainsWay Trading Up 0.4 %

NASDAQ:BWAY opened at $11.02 on Friday. The firm has a market cap of $207.40 million, a P/E ratio of 110.21 and a beta of 1.25. The stock’s 50 day simple moving average is $9.98 and its 200-day simple moving average is $9.19. BrainsWay Ltd. has a 12-month low of $4.61 and a 12-month high of $11.25.

BrainsWay (NASDAQ:BWAY) last released its earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The business had revenue of $10.50 million for the quarter, compared to analyst estimates of $10.07 million. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. During the same quarter in the previous year, the company posted ($0.01) earnings per share. Research analysts forecast that BrainsWay Ltd. will post 0.08 EPS for the current fiscal year.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.